The treatment of Common Mental Disorders across age groups: results from the 2007 Adult Psychiatric Morbidity Survey.
BACKGROUND
We investigated for the first time in a national survey whether older people were less likely than younger adults with the same symptom severity to receive treatment for Common Mental Disorders (CMD).


METHODS
We analysed data from the 2007 English Adult Psychiatric Morbidity Survey, representative of people living in private homes. 7461 (57%) people approached took part. We used the revised Clinical Interview Schedule to measure CMD symptom severity.


RESULTS
Older participants were less likely than younger adults to receive talking therapy and to have seen their GP in the last year about mental health, and more likely to receive benzodiazepines, after adjusting for CMD symptoms. Adults aged 35-74 were the most likely to take antidepressants. There was also preliminary evidence that people from non-white ethnicities were less likely to be taking antidepressants and to have seen their GP in the last year about their mental health.


CONCLUSIONS
We only recorded current treatment, and it is possible that older adults were less likely to be receiving treatments they had found unhelpful earlier in their lives. We asked people whether they had seen their GP about a mental health problem in the last year, but this question may not have detected those who attended for somatic manifestations of their anxieties.


CONCLUSIONS
Older people are less likely to receive evidence-based treatment for CMD. Managers and clinicians should prioritize reducing this inequality.
Cooper
Claudia
C
UCL Department of Mental Health Sciences (Bloomsbury campus), 2nd Floor, Charles Bell House, London, UK. c.cooper@ucl.ac.uk
Bebbington
Paul
P
McManus
Sally
S
Meltzer
Howard
H
Stewart
Robert
R
Farrell
Michael
M
King
Michael
M
Jenkins
Rachel
R
Livingston
Gill
G
D000203:Activities of Daily Living / Q000145:classification / Q000523:psychology; D000293:Adolescent; D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000453:epidemiology* / Q000628:therapy*; D001569:Benzodiazepines / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D003866:Depressive Disorder / Q000453:epidemiology* / Q000628:therapy*; D004363:Drug Utilization / Q000706:statistics & numerical data; D004739:England; D005260:Female; D058006:General Practice / Q000706:statistics & numerical data; D006297:Health Services Accessibility / Q000706:statistics & numerical data*; D006302:Health Services Research; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011287:Prejudice; D011613:Psychotherapy / Q000706:statistics & numerical data*; D012017:Referral and Consultation / Q000706:statistics & numerical data; D013222:State Medicine / Q000706:statistics & numerical data*; D014600:Utilization Review; D055815:Young Adult
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D006993:Hypnotics and Sedatives; D001569:Benzodiazepines